William Collins is a partner in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals and medical devices. Serving as his clients’ general or principal outside counsel, Mr. Collins provides strategic advice and general corporate counseling to management teams and boards while leading significant transactions on his clients’ behalf.

Mr. Collins has extensive experience with startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, acquisitions and purchase option agreements, strategic collaborations, and other complex transactions. He also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters. Advising companies throughout the full range of the corporate life cycle, Mr. Collins has worked with many of his company-side clients since their initial founding and funding. He joined Goodwin in 2010.

Experience

ERFAHRUNG

工作经历

Mr. Collins’s recent client representations include the following:

General Corporate Counseling and Significant Transactions

  • Intellia Therapeutics in connection with:
    • its formation and initial funding
    • its foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology
    • its collaboration and license agreements with Novartis and Regeneron
    • its $124.2 million initial public offering
  • Nimbus Therapeutics in connection with:
    • its multi-target strategic alliance with Celgene Corporation in immunology
    • the $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences
    • its $43 million Series B financing
  • Padlock Therapeutics in connection with:
    • its $23 million Series A financing to develop medicines targeting PADs and immune complexes in autoimmune diseases
    • its $600 million sale to Bristol-Meyers Squibb
  • Magenta Therapeutics in connection with
    •  its $48.5 million Series A financing
    • its $50 million Series B financing 
    • its strategic collaborations with Novartis and BeTheMatch
  • Relay Therapeutics in its $57 million Series A financing
  • Tango Therapeutics in its $55 million Series A financing
  • TCR2 Therapeutics in its $44.5 million Series A financing

Public Company Representation and Capital Markets Transactions

  • AMAG Pharmaceuticals in numerous follow-on equity offerings, convertible note offerings and its high-yield bond offering, raising more than $1.4 billion in capital, and its transformative acquisitions of CBR Systems and other strategic transactions 
  • Amarin Corporation in its $121.2 million, $87.5 million and $56.1 million follow-on offerings, its $53 million PIPE offering, its $150 million 144A note offering and a $118.7 privately negotiated note exchange
  • bluebird bio in its $116.1 million initial public offering

Mergers and Acquisitions

  • Ocata Therapeutics in its sale to Astellas 
  • Albany Molecular Research Inc. in its sale to The Carlyle Group and GTCR
  • Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
  • ZOLL Medical in its acquisition of Kyma Medical Systems and other business development transactions

Mr. Collins also represents leading life science venture capital firms, including Atlas Venture and Third Rock Ventures, in connection with their portfolio investments and related matters.

Professional Activities

Mr. Collins is a member of the Boston and American Bar Associations.

Professional Experience

Prior to joining Goodwin, Mr. Collins was an Economic Justice Fellow at the Lawyers’ Committee for Civil Rights, where he coordinated with community groups and local attorneys to bring pro bono business legal services to low-income and minority entrepreneurs in Eastern Massachusetts. Mr. Collins continues to be an active participant in Goodwin’s Neighborhood Business Initiative, which has for more than 15 years served the legal needs of low-income and minority entrepreneurs in the Greater Boston area.

Recognition

While attending law school, Mr. Collins was Editor-in-Chief of the Review of Banking and Financial Law.

In The News

MELDUNGEN

在新闻中

Credentials

WERDEGANG

专业资格

Education

J.D., 2009
Boston University School of Law

(cum laude)

B.S., 2006
The University of Texas at Dallas

(cum laude)

Admissions

Bar

Massachusetts
Get In Touch
KONTAKT
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
搜寻其他律师